Literature DB >> 18669616

Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease.

Jennifer B Paulson1, Martin Ramsden, Colleen Forster, Mathew A Sherman, Eileen McGowan, Karen H Ashe.   

Abstract

Transgenic mouse models that independently express mutations in amyloid precursor protein (APP) and tau have proven useful for the study of the neurological consequences of amyloid-beta (Abeta) plaque and neurofibrillary tangle pathologies. Studies using these mice have yielded essential discoveries with regard to specific aspects of neuronal dysfunction and degeneration that characterize the brain during Alzheimer's disease (AD) and other age-dependent tauopathies. Most recent transgenic studies have focused on the creation of regulatable models that allow the temporal control of transgene expression. To study a more complete model of AD pathology, we designed a new regulatable transgenic mouse that harbors both APP and tau transgenes. Here, we present a novel transgenic mouse model, rTg3696AB, which expresses human APP(NLI) and tau(P301L) driven by the CaMKII promoter system. Subsequent generation of Abeta and 4R0N tau in the brain resulted in the development of three neuropathological features of AD: Abeta plaques, neurofibrillary tangles, and neurodegeneration. Importantly, transgene expression in these mice is regulatable, permitting temporal control of gene expression and the investigation of transgene suppression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18669616      PMCID: PMC2527075          DOI: 10.2353/ajpath.2008.080175

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins.

Authors:  G Bitan; A Lomakin; D B Teplow
Journal:  J Biol Chem       Date:  2001-07-05       Impact factor: 5.157

2.  Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta.

Authors:  Minako Hoshi; Michio Sato; Shinichiro Matsumoto; Akihiko Noguchi; Kaori Yasutake; Natsuko Yoshida; Kazuki Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

3.  Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

Authors:  Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

4.  Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques.

Authors:  Edward A Stern; Brian J Bacskai; Gregory A Hickey; Frank J Attenello; Julianne A Lombardo; Bradley T Hyman
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

5.  FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain.

Authors:  F Lim; F Hernández; J J Lucas; P Gómez-Ramos; M A Morán; J Avila
Journal:  Mol Cell Neurosci       Date:  2001-12       Impact factor: 4.314

6.  Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease.

Authors:  B Urbanc; L Cruz; R Le; J Sanders; K Hsiao Ashe; K Duff; H E Stanley; M C Irizarry; B T Hyman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-09       Impact factor: 11.205

7.  Neurodegenerative disease: amyloid pores from pathogenic mutations.

Authors:  Hilal A Lashuel; Dean Hartley; Benjamin M Petre; Thomas Walz; Peter T Lansbury
Journal:  Nature       Date:  2002-07-18       Impact factor: 49.962

8.  In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories.

Authors:  J D D'Amore; S T Kajdasz; M E McLellan; B J Bacskai; E A Stern; B T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2003-02       Impact factor: 3.685

9.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms.

Authors:  Cathy Andorfer; Yvonne Kress; Marisol Espinoza; Rohan de Silva; Kerry L Tucker; Yves-Alain Barde; Karen Duff; Peter Davies
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

10.  Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations.

Authors:  Julianne A Lombardo; Edward A Stern; Megan E McLellan; Stephen T Kajdasz; Gregory A Hickey; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2003-11-26       Impact factor: 6.167

View more
  28 in total

1.  Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats.

Authors:  Gao-Shang Chai; Dong-Xiao Duan; Rong-Hong Ma; Jian-Ying Shen; Hong-Lian Li; Zhi-Wei Ma; Yu Luo; Lu Wang; Xin-Hua Qi; Qun Wang; Jian-Zhi Wang; Zelan Wei; Darrell D Mousseau; Li Wang; Gongping Liu
Journal:  Neurosci Bull       Date:  2014-11-12       Impact factor: 5.203

2.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

Review 3.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

4.  Deciphering the Biochemical Pathway and Pharmacokinetic Study of Amyloid βeta-42 with Superparamagnetic Iron Oxide Nanoparticles (SPIONs) Using Systems Biology Approach.

Authors:  Aman Chandra Kaushik; Ajay Kumar; Vivek Dhar Dwivedi; Shiv Bharadwaj; Sanjay Kumar; Kritika Bharti; Pavan Kumar; Ravi Kumar Chaudhary; Sarad Kumar Mishra
Journal:  Mol Neurobiol       Date:  2017-05-06       Impact factor: 5.590

5.  In vivo characterization of a bigenic fluorescent mouse model of Alzheimer's disease with neurodegeneration.

Authors:  Sarah E Crowe; Graham C R Ellis-Davies
Journal:  J Comp Neurol       Date:  2013-07-01       Impact factor: 3.215

Review 6.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

7.  Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression.

Authors:  Holly C Hunsberger; Daniel S Weitzner; Carolyn C Rudy; James E Hickman; Eric M Libell; Rebecca R Speer; Greg A Gerhardt; Miranda N Reed
Journal:  J Neurochem       Date:  2015-08-13       Impact factor: 5.372

8.  Regulation of IL-1β-induced cyclooxygenase-2 expression by interactions of Aβ peptide, apolipoprotein E and nitric oxide in human neuroglioma.

Authors:  Anju S Samy; Orisa J Igwe
Journal:  J Mol Neurosci       Date:  2011-11-19       Impact factor: 3.444

9.  Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease.

Authors:  Xifei Yang; George Dai; Geng Li; Edward S Yang
Journal:  J Mol Neurosci       Date:  2009-10-16       Impact factor: 3.444

10.  Riluzole rescues alterations in rapid glutamate transients in the hippocampus of rTg4510 mice.

Authors:  Holly C Hunsberger; James E Hickman; Miranda N Reed
Journal:  Metab Brain Dis       Date:  2016-01-08       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.